Regulatory Focus™ > News Articles > EMA Tightens Conflict-of-Interest Policies

EMA Tightens Conflict-of-Interest Policies

Posted 04 April 2012 | By Alexander Gaffney, RAC 

The European Medicines Agency (EMA) announced it will, effective immediately, be tightening its conflict-on-interest policies for scientific experts and members of advisory committees.

The policy was announced 3 April after being endorsed by EMA's Management Board on 22 March 2012.

"The updated policy gives clearer guidance on the involvement of experts in academic trials and publicly funded research," explained EMA in a statement. "It aligns restrictions for the different roles in the scientific decision-making process and tightens the rules on grants from the pharmaceutical industry."

Along with the new standards, EMA also announced a new 11-step procedure on "suspected breaches of trust" for incomplete or incorrect declarations of interest and a new policy for conflicts of interest among Management Board members.


Read more:

EMA - European Medicines Agency tightens conflicts-of-interests policies with immediate effect

European Medicines Agency policy on the handling of conflicts of interests of the Management Board

European Medicines Agency policy on the handling of conflicts of interests of scientific committee members and experts

European Medicines Agency breach of trust procedure on conflicts of interests for scientific committee members and experts

Public declaration of interests and confidentiality undertaking of European Medicines Agency Management Board


Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe